Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
about
Targeting BMP signalling in cardiovascular disease and anaemiaIntravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension.Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
P2860
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@ast
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@en
type
label
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@ast
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@en
prefLabel
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@ast
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@en
P2093
P2860
P50
P1476
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
@en
P2093
Adeline Roux
Anne-Emmanuelle Fargeton
David Ternant
Evelyne Decullier
Frédéric Faure
Isabelle Ginon
Marie-France Carette
Nicolas Azzopardi
Pascal Lacombe
Pierre-Yves Hatron
P2860
P304
P356
10.1080/19420862.2015.1022693
P577
2015-01-01T00:00:00Z